Therapeutic effect of Cerebrolysin on reducing impaired cerebral endothelial cell permeability.
Journal
Neuroreport
ISSN: 1473-558X
Titre abrégé: Neuroreport
Pays: England
ID NLM: 9100935
Informations de publication
Date de publication:
24 03 2021
24 03 2021
Historique:
entrez:
4
3
2021
pubmed:
5
3
2021
medline:
15
12
2021
Statut:
ppublish
Résumé
Cerebrolysin has been shown to promote neurovascular protection and repair in preclinical models of stroke and neural injury and is demonstrating promise for stroke and neural injury therapeutic application in the clinic. The effect of Cerebrolysin on the human cerebral endothelial cell function has not been investigated. Using an in-vitro cerebral endothelial cell permeability assay and western blot analyses of tight junction and proinflammatory and procoagulant proteins, the present study showed that tissue plasminogen activator (tPA) and fibrin substantially impaired human cerebral endothelial cell barrier function and increased permeability, which persisted for at least 24 h. western blot analysis revealed that tPA and fibrin significantly increased proinflammatory and procoagulation proteins of intercellular adhesion molecule 1, high mobility group box 1, tumor necrosis factor α and phosphorylated nuclear factor kappa B-p65, and significantly reduced tight junction proteins zonular 1, occludin and claudin. However, Cerebrolysin significantly diminished and reversed tPA- and fibrin-impaired endothelial cell permeability, which was associated with significant reductions of tPA- and fibrin-augmented proinflammatory and procoagulation proteins and significant elevations of tPA- and fibrin-decreased tight junction proteins. The beneficial effect of Cerebrolysin appears specific because cerebroprotein hydrolysate, with a distinct peptide composition, failed to show the reduction of tPA- and fibrin-impaired permeability. These data indicate that cererbrolysin has a therapeutic effect on tPA- and fibrin-impaired cerebral endothelial cell permeability by reducing proinflammatory and procoagulation proteins and by elevating tight junction proteins.
Identifiants
pubmed: 33661804
doi: 10.1097/WNR.0000000000001598
pii: 00001756-202103020-00004
doi:
Substances chimiques
Amino Acids
0
Neuroprotective Agents
0
cerebrolysin
37KZM6S21G
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
359-366Informations de copyright
Copyright © 2021 The Author(s). Published by Wolters Kluwer Health, Inc.
Références
Brainin M. Cerebrolysin: a multi-target drug for recovery after stroke. Expert Rev Neurother. 2018; 18:681–687.
Masliah E, Díez-Tejedor E. The pharmacology of neurotrophic treatment with Cerebrolysin: brain protection and repair to counteract pathologies of acute and chronic neurological disorders. Drugs Today (Barc). 2012; 48 (Suppl A):3–24.
Zhang L, Chopp M, Lu M, Zhang T, Winter S, Doppler E, et al. Cerebrolysin dose-dependently improves neurological outcome in rats after acute stroke: a prospective, randomized, blinded, and placebo-controlled study. Int J Stroke. 2016; 11:347–355.
Zhang Y, Chopp M, Meng Y, Zhang ZG, Doppler E, Mahmood A, Xiong Y. Improvement in functional recovery with administration of Cerebrolysin after experimental closed head injury. J Neurosurg. 2013; 118:1343–1355.
Ren J, Sietsma D, Qiu S, Moessler H, Finklestein SP. Cerebrolysin enhances functional recovery following focal cerebral infarction in rats. Restor Neurol Neurosci. 2007; 25:25–31.
Sweeney MD, Zhao Z, Montagne A, Nelson AR, Zlokovic BV. Blood-brain barrier: from physiology to disease and back. Physiol Rev. 2019; 99:21–78.
Zhang L, Zhang ZG, Chopp M. The neurovascular unit and combination treatment strategies for stroke. Trends Pharmacol Sci. 2012; 33:415–422.
Petersen MA, Ryu JK, Akassoglou K. Fibrinogen in neurological diseases: mechanisms, imaging and therapeutics. Nat Rev Neurosci. 2018; 19:283–301.
Merlini M, Rafalski VA, Rios Coronado PE, Gill TM, Ellisman M, Muthukumar G, et al. Fibrinogen induces microglia-mediated spine elimination and cognitive impairment in an Alzheimer’s disease model. Neuron. 2019; 101:1099–1108.e6.
Teng H, Zhang ZG, Wang L, Zhang RL, Zhang L, Morris D, et al. Coupling of angiogenesis and neurogenesis in cultured endothelial cells and neural progenitor cells after stroke. J Cereb Blood Flow Metab. 2008; 28:764–771.
Li C, Zhang L, Wang C, Teng H, Fan B, Chopp M, Zhang ZG. N-acetyl-seryl-aspartyl-lysyl-proline augments thrombolysis of tPA (tissue-type plasminogen activator) in aged rats after stroke. Stroke. 2019; 50:2547–2554.
Siddharthan V, Kim YV, Liu S, Kim KS. Human astrocytes/astrocyte-conditioned medium and shear stress enhance the barrier properties of human brain microvascular endothelial cells. Brain Res. 2007; 1147:39–50.
Niego B, Freeman R, Puschmann TB, Turnley AM, Medcalf RL. t-PA-specific modulation of a human blood-brain barrier model involves plasmin-mediated activation of the Rho kinase pathway in astrocytes. Blood. 2012; 119:4752–4761.
Gu B, Piebalgs A, Huang Y, Longstaff C, Hughes AD, Chen R, et al., Mathematical modelling of intravenous thrombolysis in acute ischaemic stroke: effects of dose regimens on levels of fibrinolytic proteins and clot lysis time. Pharmaceutics. 2019; 11:111.
Tennent GA, Brennan SO, Stangou AJ, O’Grady J, Hawkins PN, Pepys MB. Human plasma fibrinogen is synthesized in the liver. Blood. 2007; 109:1971–1974.
An L, Han X, Li H, Ma Y, Shi L, Xu G, et al. Effects and mechanism of cerebroprotein hydrolysate on learning and memory ability in mice. Genet Mol Res. 2016; 15: gmr.15038804.
Levi M, van der Poll T. Inflammation and coagulation. Crit Care Med. 2010; 38:S26–S34.
Levi M, van der Poll T. Coagulation and sepsis. Thromb Res. 2017; 149:38–44.
Zhang ZG, Chopp M. Neurorestorative therapies for stroke: underlying mechanisms and translation to the clinic. Lancet Neurol. 2009; 8:491–500.
Cui S, et al. Cerebrolysin for vascular dementia. Cochrane Database Syst Rev. 2019; 2019:CD008900.
Ziganshina LE, Abakumova T, Vernay L. Cerebrolysin for acute ischaemic stroke. Cochrane Database Syst Rev. 2016; 12:CD007026.
Keep RF, Andjelkovic AV, Xiang J, Stamatovic SM, Antonetti DA, Hua Y, Xi G. Brain endothelial cell junctions after cerebral hemorrhage: changes, mechanisms and therapeutic targets. J Cereb Blood Flow Metab. 2018; 38:1255–1275.
Keep RF, Xiang J, Ennis SR, Andjelkovic A, Hua Y, Xi G, Hoff JT. Blood-brain barrier function in intracerebral hemorrhage. Acta Neurochir Suppl. 2008; 105:73–77.
Fiuza C, Bustin M, Talwar S, Tropea M, Gerstenberger E, Shelhamer JH, Suffredini AF. Inflammation-promoting activity of HMGB1 on human microvascular endothelial cells. Blood. 2003; 101:2652–2660.
Zhang J, Takahashi HK, Liu K, Wake H, Liu R, Maruo T, et al. Anti-high mobility group box-1 monoclonal antibody protects the blood-brain barrier from ischemia-induced disruption in rats. Stroke. 2011; 42:1420–1428.